Horizon Pharma Inc. (HZNP) Trading Up 2.7%
Horizon Pharma Inc. (NASDAQ:HZNP) shares were up 2.7% during trading on Wednesday . The company traded as high as $19.95 and last traded at $19.61, with a volume of 1,281,854 shares changing hands. The stock had previously closed at $19.10.
A number of research analysts recently commented on HZNP shares. Vetr downgraded shares of Horizon Pharma from a “strong-buy” rating to a “buy” rating and set a $19.44 price target for the company. in a report on Monday, April 4th. Cowen and Company reaffirmed a “buy” rating on shares of Horizon Pharma in a report on Saturday, April 2nd. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $44.00 price target on shares of Horizon Pharma in a report on Wednesday, April 13th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Horizon Pharma in a report on Tuesday, April 12th. Finally, Mizuho reaffirmed a “buy” rating and issued a $34.00 price target on shares of Horizon Pharma in a report on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Horizon Pharma has a consensus rating of “Buy” and a consensus price target of $29.23.
The firm has a market cap of $3.18 billion and a P/E ratio of 257.79. The stock’s 50-day moving average is $17.79 and its 200 day moving average is $16.90.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.04. The business had revenue of $204.70 million for the quarter, compared to analysts’ expectations of $197.73 million. During the same period in the prior year, the company posted $0.18 EPS. The firm’s revenue was up 80.9% on a year-over-year basis. On average, equities research analysts predict that Horizon Pharma Inc. will post $2.35 EPS for the current year.
In related news, Director Virinder Nohria sold 25,000 shares of the company’s stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the sale, the director now owns 189,836 shares of the company’s stock, valued at approximately $3,358,198.84. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
A number of hedge funds have made changes to their positions in HZNP. Airain ltd acquired a new stake in shares of Horizon Pharma during the fourth quarter valued at about $2,123,000. Dimensional Fund Advisors LP boosted its stake in shares of Horizon Pharma by 104.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 557,772 shares of the biopharmaceutical company’s stock valued at $12,089,000 after buying an additional 284,359 shares in the last quarter. Redwood Investments LLC boosted its stake in shares of Horizon Pharma by 43.8% in the fourth quarter. Redwood Investments LLC now owns 111,682 shares of the biopharmaceutical company’s stock valued at $2,420,000 after buying an additional 34,008 shares in the last quarter. Hodges Capital Management Inc. boosted its stake in shares of Horizon Pharma by 4.1% in the fourth quarter. Hodges Capital Management Inc. now owns 1,571,794 shares of the biopharmaceutical company’s stock valued at $34,061,000 after buying an additional 61,454 shares in the last quarter. Finally, Systematic Financial Management LP boosted its stake in shares of Horizon Pharma by 100.4% in the fourth quarter. Systematic Financial Management LP now owns 152,340 shares of the biopharmaceutical company’s stock valued at $3,301,000 after buying an additional 76,335 shares in the last quarter.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.